Targeting inflammatory pathways in myocardial infarction

European Journal of Clinical Investigation

Volumn 43, Issue 9, 2013, Pages 986-995

  Christia, Panagiota ^a   Frangogiannis, Nikolaos G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Animal models; Cytokine; Inflammation; Leucocytes; Myocardial infarction; Remodelling

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; COLONY STIMULATING FACTOR 1; COMPLEMENT COMPONENT C5A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; L SELECTIN; LEUKOTRIENE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE ACTIVATING FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

AGE; CYTOKINE PRODUCTION; DIASTOLIC DYSFUNCTION; GENDER; GENETIC PREDISPOSITION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; INFLAMMATION; LEUKOCYTE MIGRATION; MICROVASCULAR ENDOTHELIAL CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION;

ANIMAL MODELS; CYTOKINE; INFLAMMATION; LEUCOCYTES; MYOCARDIAL INFARCTION; REMODELLING;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES; ANTIGENS, CD11; ANTIGENS, CD18; CHEMOKINES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; INTEGRINS; LEUKOCYTES; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCYTES, CARDIAC; VENTRICULAR REMODELING;

EID: 84881668804     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12118     Document Type: Review

References (69)

1. Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM et al. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study. Circulation 2009;119:1203-10.
2. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008;118:2057-62.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
4. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58:88-111.
5. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A et al. The critical role of endogenous Thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation 2005;111:2935-42.
6. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-9.
7. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-37.
8. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53.
9. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159-73.
10. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975;56:740-50.
11. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885-900.
12. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
13. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121:80-90.
14. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5.
15. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012;485:251-5.
16. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011;108:1133-45.
17. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008;102:257-64.
18. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-9.
19. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011;123:594-604.
20. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 2011;108:19725-30.
21. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008;173:57-67.
22. Chen W, Frangogiannis NG. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta 2013;1833:945-53.
23. Palazzo AJ, Jones SP, Anderson DC, Granger DN, Lefer DJ. Coronary endothelial P-selectin in pathogenesis of myocardial ischemia-reperfusion injury. Am J Physiol 1998;275:H1865-72.
24. Frangogiannis NG, Mendoza LH, Lewallen M, Michael LH, Smith CW, Entman ML. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J 2001;15:1428-30.
25. Kumar AG, Ballantyne CM, Michael LH, Kukielka GL, Youker KA, Lindsey ML et al. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation 1997;95:693-700.
26. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998;98:699-710.
27. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007;97:738-47.
28. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6.
29. Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol 2011;32:461-9.
30. Simpson PJ, Todd RF 3rd, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988;81:624-9.
31. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol 1998;275:H2300-7.
32. Woodfin A, Voisin MB, Beyrau M, Colom B, Caille D, Diapouli FM et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol 2011;12:761-9.
33. Corada M, Chimenti S, Cera MR, Vinci M, Salio M, Fiordaliso F et al. Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102:10634-9.
34. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-47.
35. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 2012;125:1652-63.
36. Frangogiannis NG, Mendoza LH, Ren G, Akrivakis S, Jackson PL, Michael LH et al. MCSF expression is induced in healing myocardial infarcts and may regulate monocyte and endothelial cell phenotype. Am J Physiol Heart Circ Physiol 2003;285:H483-92.
37. Frantz S, Hofmann U, Fraccarollo D, Schafer A, Kranepuhl S, Hagedorn I et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J 2013;27:871-81.
38. Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, Frangogiannis NG. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol 2010;176:2177-87.
39. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 2006;48:2315-23.
40. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177:1576-91.
41. Frangogiannis NG, Mendoza LH, Lindsey ML, Ballantyne CM, Michael LH, Smith CW et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000;165:2798-808.
42. Zymek P, Nah DY, Bujak M, Ren G, Koerting A, Leucker T et al. Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodeling. Cardiovasc Res 2007;74:313-22.
43. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998;30:1559-69.
44. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011;51:600-6.
45. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007;74:184-95.
46. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007;116:2127-38.
47. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 2010;107:418-28.
48. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012;92:635-88.
49. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17:581-8.
50. Chen W, Saxena A, Li N, Sun J, Gupta A, Lee DW et al. Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts. Arterioscler Thromb Vasc Biol 2012;32:2598-608.
51. Cochain C, Auvynet C, Poupel L, Vilar J, Dumeau E, Richart A et al. The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 2012;32:2206-13.
52. Arai M, Lefer DJ, So T, DiPaula A, Aversano T, Becker LC. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996;27:1278-85.
53. Aversano T, Zhou W, Nedelman M, Nakada M, Weisman H. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J Am Coll Cardiol 1995;25:781-8.
54. Lefer DJ, Shandelya SM, Serrano CV Jr, Becker LC, Kuppusamy P, Zweier JL. Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation 1993;88:1779-87.
55. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88:1237-43.
56. Simpson PJ, Todd RF 3rd, Mickelson JK, Fantone JC, Gallagher KP, Lee KA et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 1990;81:226-37.
57. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001;104:2778-83.
58. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-204.
59. Rusnak JM, Kopecky SL, Clements IP, Gibbons RJ, Holland AE, Peterman HS et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001;88:482-7.
60. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
61. Briaud SA, Ding ZM, Michael LH, Entman ML, Daniel S, Ballantyne CM. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. Am J Physiol Heart Circ Physiol 2001;280:H60-7.
62. Bujak M, Kweon HJ, Chatila K, Li N, Taffet G, Frangogiannis NG. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Coll Cardiol 2008;51:1384-92.
63. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010;105:1371-7 e1.
64. Carrabba N, Valenti R, Parodi G, Santoro GM, Antoniucci D. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. Circulation 2004;110:1974-9.
65. Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Current Atherosclerosis Reports 2009;11:131-8.
66. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007;50:2117-24.
67. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010;121:1645-54.
68. Frangogiannis NG. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res 2012;159:197-204.
69. Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC, Jennings RB et al. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 1993;87:526-35.